Hexapradol

Hexapradol

SCHEMBL1816624

CCCCCC(N)C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
MAPK1 P28482 1/20 0.53
CSNK1E P49674 1/20 0.46
MEN1 O00255 1/20 0.44
TTR P02766 1/20 0.44
KMT2A Q03164 1/20 0.44
KIF11 P52732 5/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CNR2 P34972 1/20 0.39
CES2 O00748 2/20 0.38
CES1 P23141 2/20 0.38
KCNA5 P22460 1/20 0.37
KCNH2 Q12809 1/20 0.37
OPRM1 P35372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8132778 0.87 LMNA (0.58) KDM4ELMNAMAPK1MEN1TTR
SCHEMBL11411634 0.84 MEN1 (0.45) KDM4ELMNAMAPK1CSNK1EMEN1
SCHEMBL7993168 0.82 CSNK1E (0.45) KDM4ELMNAMAPK1CSNK1EKIF11
Water SCHEMBL11570733 0.81 CSNK1E (0.44) CSNK1EKIF11ALDH1A1CNR2CES2
SCHEMBL17351131 0.80 CSNK1E (0.44) KDM4ELMNAMAPK1CSNK1EKIF11
SCHEMBL7859912 0.80 LMNA (0.61) KDM4ELMNAMAPK1MEN1TTR
SCHEMBL10726204 0.79 CSNK1E (0.46) CSNK1EKIF11ALDH1A1CES2CES1
SCHEMBL483815 0.79 CSNK1E (0.46) CSNK1EKIF11ALDH1A1CES2CES1
Water SCHEMBL11572540 0.79 CSNK1E (0.46) CSNK1EKIF11ALDH1A1CES2CES1
Water SCHEMBL11433620 0.79 CSNK1E (0.43) CSNK1EKIF11ALDH1A1CNR2CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
WO-2025129358-A1 STABLE FILM FORMULATIONS FOR HIGH LOADING OF LOW MELTING POINT ACTIVES INTELGENX CORP. (CA) 2025-06-26 WO disclosed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 US disclosed
CN-102802601-B Tyr-Arg dipeptides is preventing the cosmetic applications of skin sagging 赛德玛公司 2016-08-17 CN disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US disclosed
CN-101854907-B Cosmetic composition comprising hydroxymethionine and 3-aminopropanesulfonic acid SEDERMA SA 2014-06-18 CN disclosed
EP-1341527-A1 PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX ALTANA Pharma AG (DE) 2003-09-10 EP disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
WO-2002045693-A1 PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX ALTANA PHARMA AG (DE) 2002-06-13 WO disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 KDM4E 4426/4885LMNA 1552/4885MAPK1 4783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.